Rigel Pharmaceuticals, Inc. (RIGL) Cash Flow Statement

The OCF/NI ratio swung from 1.77 in 2026Q2 to 0.08 in 2025Q4, indicating that reported net income is not consistently backed by cash generation. The $268.1M net income in 2025Q4 appears to be driven by a one-time tax valuation allowance release, as operating cash flow was only $22.0M. Investors should strip out this non-cash benefit to assess underlying cash conversion, which otherwise appears healthy with OCF/NI above 1 in several quarters.

The trajectory of FCF is highly erratic, with negative quarters in 2024Q1 and 2025Q1, followed by strong positive quarters. This volatility suggests that FCF is not yet a reliable indicator of sustainable profitability, as it is heavily influenced by the timing of collaboration milestones and working capital changes. The latest quarter's 38.9% FCF margin is encouraging, but the pattern of swings warrants caution in extrapolating forward.

Rigel's capital expenditures are essentially nil, reflecting its reliance on contract manufacturing and outsourced production for its small-molecule drugs. This low capital intensity allows nearly all operating cash flow to convert to free cash flow, as seen in quarters where FCF equals OCF. The absence of significant capex suggests that the company does not require heavy investment to maintain its current operations, though future pipeline development may require increased spending.

The working capital changes are substantial relative to operating cash flow, often exceeding $10M in magnitude. For instance, 2026Q1 saw a -$12.4M working capital drag that reduced OCF to just $2.7M, while 2026Q2's +$11.6M boost helped push OCF to $30.7M. This suggests that Rigel's cash flow is sensitive to the timing of collections from partners and payments to suppliers, which may not reflect underlying operational performance.

The only capital deployment activity in the data is a $3.7M share repurchase in 2026Q2, with no dividends or significant acquisitions. This suggests that management is returning modest amounts to shareholders while preserving cash for operational needs and potential pipeline investments. The lack of large-scale deployment may indicate a preference for maintaining a strong cash position, which is consistent with the company's low debt levels.

The cumulative divergence between net income and operating cash flow is stark, with net income totaling $410.5M versus OCF of $140.5M. This gap is primarily driven by the $268.1M net income in 2025Q4, which appears to be a non-cash tax benefit, and recurring stock-based compensation expenses. Investors should recognize that reported profitability overstates cash generation, and normalized earnings power is likely lower than headline figures suggest.